MedicineHematologyOncologyHematologic OncologyHematopathologyClinical HematologyHematocrit RegulationHematologic DisordersHematologic MalignanciesHematologic PathologyLymphoid TumorsHematocrit EffectsHematologic Outcome AssessmentHodgkin Lymphoma TherapyPrognostic ModelsPrognostic Prediction
Pretreatment hematocrit in 117 advanced-stage Hodgkin's disease patients treated with a combined modality therapy program was evaluated as an independent prognostic variable with regard to survival and relapse-free survival. Age greater than 40 years, and multiple extranodal sites of involvement were found to be statistically significant independent negative prognostic factors with regard to survival. Pretreatment hematocrit, however, was not an independent negative prognostic variable.
4
Prognostic factors in 454 cases of Hodgkin's disease.
M Tubiana, E Attié, R Flamant et al. · PubMed · 1971 · 126 citations
Medicine, Hematology, Pathology +11
Curative potential of combined modality therapy for advanced Hodgkin's disease
Leonard R. Farber, Leonard R. Prosnitz, E Cadman et al. · Cancer · 1980 · 47 citations · Full text
Medicine, Oncology, Chemotherapy +14
A clinical study of Hodgkin's disease.
J. Crosbie · PubMed · 1962 · 12 citations